News / Health

MannKind's Inhaled Insulin Offers Diabetics Freedom from Shots

Reuters
An inhaled insulin device made by MannKind Corp proved more effective than injected and oral treatments in trials, potentially improving the quality of life for millions of diabetics and creating a multi-billion dollar opportunity for the company.

MannKind shares rose as much as 27 percent in morning trade.

The product, Afrezza, is a whistle-sized inhaler that delivers powdered insulin to adults with Type 1 and Type 2 diabetes. Given the ease of use compared with regular insulin shots, it has the potential to capture a big share of the global insulin market.

The number of diabetics worldwide is projected to cross half a billion by 2030. According to a July report by Transparency Market Research, the global insulin market is expected to reach $32 billion in 2018.

MLV & Co analyst Graig Suvannavejh expects Afrezza to get regulatory approval, but said the bigger question is whether the company can successfully commercialize the product.

“I think it really will depend on who the exact partner is, as this product is going to require a lot of education, a lot of heavy lifting,” Suvannavejh said.

He estimates U.S. and European sales of about $3 billion for Afrezza by 2025.

The inhaled insulin market has seen high-profile commercial failure in the past. Pfizer Inc withdrew Exubera in 2007 due to poor sales. The large size of the device and a high price were blamed for its failure.

Suvannavejh said a potential partner for MannKind could come from among such major diabetes players as Denmark's Novo Nordisk , French drugmaker Sanofi, Bristol-Myers Squibb, Merck & Co Inc, Eli Lilly & Co  and Johnson & Johnson.

Sweet data

Afrezza is a flagship product for MannKind, whose shares have risen nearly 50 percent over the past three months in anticipation of positive data from the two trials.

Results from the two studies included a reduction in fasting blood glucose levels and lower incidences of hypoglycemia - a side-effect of taking insulin that leads to dangerously low sugar levels.

MannKind said it expects to submit data from the trials to the U.S. Food and Drug Administration in the fourth quarter ending December.

The FDA rejected Afrezza in early 2011 and asked the company to conduct two clinical trials to prove that the second-generation of the device was equivalent to its first-generation inhaler.

MannKind had initially filed for approval based on data from the first-generation device, before updating the application to the newer device.

The first trial, named Study 171, compared Afrezza with Novo Nordisk's injected insulin NovoLog, and showed that the second-generation device was comparable to the first-generation inhaler.

The second trial, named Study 175, showed Afrezza was better in reducing patients' A1C levels - a measure of blood glucose control - compared to oral therapy.

Diabetics typically start out on oral medicine but often need to move on to insulin shots to regulate blood-sugar levels.

The company has another experimental diabetes therapy - called MKC253 - in development, along with two potential cancer treatments.

MannKind shares were trading up 15 percent at $7.91 on the Nasdaq on Wednesday.

You May Like

EU Court Fines Poland for Hosting CIA 'Black Sites'

Ruling is first time a court has acknowledged suspects were held and tortured at the sites, under US program launched following the 9/11 terrorist attacks More

Migrant Issues Close to Home Spur Groups to Take Action

Groups placing water, food in the desert, or aiding detainees after release, have one common goal: no more deaths of migrants crossing illegally into the US More

Video At AIDS Conference, Prevention Pill Stirs Excitement

Truveda shows promise, spurring debate over access and other approaches More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Treatment for Childhood Epilepsy Heats up Medical Marijuana Debatei
X
Shelley Schlender
July 24, 2014 6:43 PM
In the United States, marijuana is classed as an illegal drug by the federal government. But nearly half the states have legalized it, to some degree. Proponents say some strains of marijuana might have exceptional health benefits, for treating pain or inflammation in chronic conditions such as cancer, multiple sclerosis and epilepsy. Shelley Schlender reports on a strain of medical marijuana developed in Colorado that is reputed to reduce seizures in childhood epilepsy
Video

Video Treatment for Childhood Epilepsy Heats up Medical Marijuana Debate

In the United States, marijuana is classed as an illegal drug by the federal government. But nearly half the states have legalized it, to some degree. Proponents say some strains of marijuana might have exceptional health benefits, for treating pain or inflammation in chronic conditions such as cancer, multiple sclerosis and epilepsy. Shelley Schlender reports on a strain of medical marijuana developed in Colorado that is reputed to reduce seizures in childhood epilepsy
Video

Video Airbus Adds Metal 3D Printed Parts to New Jets

By the end of this year, European aircraft manufacturing consortium Airbus plans to deliver the first of its new, extra-wide-body passenger jets, the A350-XWB. Among other technological innovations, the new plane will also incorporate metal parts made in a 3-D printer. VOA's George Putic has more.
Video

Video Death Toll From Israel-Gaza Conflict Surpasses 700

Gaza officials say a shelling hit a compound housing a United Nations-run school in the Gaza Strip, killing more than a dozen people, during an Israeli offensive in the area. Heavy fighting between the Israeli military and Hamas militants continued on Thursday, pushing up the death toll. So far, more than 730 Palestinians and 35 Israelis have been killed in the conflict. VOA's Scott Bobb has the latest from Jerusalem.
Video

Video AIDS Conference Welcomes Exciting Developments in HIV Treatment, Prevention

Significant strides have been made in recent years toward the treatment and prevention of HIV, the virus that causes AIDS. This year, at the International AIDS Conference, the AIDS community welcomed progress on a new pill that may prevent transmission of the deadly virus. VOA’s Anita Powell reports from Melbourne, Australia.
Video

Video Israel Targets Gaza Supply Tunnels

The Israeli military has launched a ground operation in Gaza to destroy the myriad tunnels that may have been used to smuggle weapons to Hamas. VOA's Zlatica Hoke reports that could mean more hardship for the people of Gaza, who obtain some of their essential supplies through these underground passages
Video

Video Researchers Target Low-Cost Avatar Technology

Scientists at the University of Southern California Institute for Creative Technologies say 3-dimensional representations could revolutionize social media. Elizabeth Lee has more from Los Angeles.
Video

Video IAEA: Iran Turns its Enriched Uranium Into Less Harmful Form

Iran has converted its stockpiles of enriched uranium into a less dangerous form that is more difficult to use for nuclear weapons, according to the United Nations’ Atomic Energy Agency. The move complies with an interim deal reached with Western powers on Iran's nuclear program last year, in exchange for easing of sanctions. Henry Ridgwell reports for VOA from London.
Video

Video In Cambodia, HIV Diagnosis Brings Deadly Shame

Although HIV/AIDS is now a treatable condition, a positive diagnosis is still a life altering experience. In Cambodia, people living with HIV are often disowned by friends, family and the community. This humiliation can be unbearable. We bring you one Cambodian woman’s struggle to overcome a life tragedy and her own HIV positive diagnosis.

AppleAndroid